Business · 26/02/2010

National Institutes of Health to Consider Exclusive Patent License for Glaucoma Treatment

The National Institutes of Health is issuing a notice under 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i) regarding the potential grant of an exclusive patent license for the use of adenosine receptor antagonists in treating glaucoma, as described in several patent applications filed by the NIH.